PHVS Pharvaris
- 21.900
- -0.200-0.90%
Pharvaris News
Vicore Expands and Strengthens Its Board of Directors
STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
ZUG, Switzerland, May 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema
Pharvaris's Promising Drug Candidate Deucrictibant Bolsters Buy Rating
Pharvaris Is Maintained at Outperform by Wedbush
Pharvaris Is Maintained at Outperform by Wedbush
Wedbush Adjusts Pharvaris' Price Target to $31 From $35, Maintains Outperform Rating
Wedbush Adjusts Pharvaris' Price Target to $31 From $35, Maintains Outperform Rating.
Analysts Are Bullish on Top Healthcare Stocks: Steris (STE), Pharvaris (PHVS)
Pharvaris Q1 2024 Adj EPS €(0.52) Beats €(0.56) Estimate
Pharvaris Q1 2024 Adj EPS €(0.52) Beats €(0.56) Estimate
Pharvaris Advances HAE Treatment in Solid Q1 2024
Pharvaris 1Q EUR Loss/Shr 52c >PHVS
Pharvaris 1Q EUR Loss/Shr 52c >PHVS
Pharvaris | 6-K: Report of foreign private issuer (related to financial reporting)
Press Release: Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update -- RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, c
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
Form 144 | Pharvaris(PHVS.US) Officer Proposes to Sell 417.4K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 23, $Pharvaris(PHVS.US)$ Officer MORGAN CONN intends to sell 20,000 shares of its common stock on Apr 23, with a total market value of approximately $417.4K. MORGAN CONN
Damo: Maintaining the Pharvaris (PHVS.US) rating, adjusted from an increase to an increase in holdings rating, and the target price was adjusted from $34.00 to $34.00.
Damo: Maintaining the Pharvaris (PHVS.US) rating, adjusted from an increase to an increase in holdings rating, and the target price was adjusted from $34.00 to $34.00.
Morgan Stanley Maintains Overweight on Pharvaris, Maintains $34 Price Target
Morgan Stanley analyst Matthew Harrison maintains Pharvaris (NASDAQ:PHVS) with a Overweight and maintains $34 price target.
Form 144 | Pharvaris(PHVS.US) Officer Proposes to Sell 311.9K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 15, $Pharvaris(PHVS.US)$ Officer MORGAN CONN intends to sell 14,242 shares of its common stock on Apr 15, with a total market value of approximately $311.9K. Source: Ann
Pharvaris Is Maintained at Overweight by Morgan Stanley
Pharvaris Is Maintained at Overweight by Morgan Stanley
Damo: Maintaining the Pharvaris (PHVS.US) rating, adjusted from an increase to an increase in holdings rating, and the target price was adjusted from $35.00 to $34.00.
Damo: Maintaining the Pharvaris (PHVS.US) rating, adjusted from an increase to an increase in holdings rating, and the target price was adjusted from $35.00 to $34.00.
Morgan Stanley Maintains Overweight on Pharvaris, Lowers Price Target to $34
Morgan Stanley analyst Matthew Harrison maintains Pharvaris with a Overweight and lowers the price target from $35 to $34.
Pharvaris Shares Are Trading Lower After the Company Filed for a Mixed Shelf Offering.
Pharvaris Shares Are Trading Lower After the Company Filed for a Mixed Shelf Offering.
Analysis
Price Target
No Data
